# Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

> **NCT06563869** · PHASE3 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** PEG-rhG-GSF

## Key facts

- **NCT ID:** NCT06563869
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-02
- **Primary completion:** 2025-11-22
- **Final completion:** 2026-11-22
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06563869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06563869, "Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06563869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*